Freeman ME, Kanyicska B, Lerant A, Nagy G, Prolactin (2000) Structure, Function, and regulation of secretion. Physiol Rev 80(4):1523–1631. https://doi.org/10.1152/physrev.2000.80.4.1523

Article  CAS  PubMed  Google Scholar 

Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S (2023) Diagnosis and management of Prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722–740. https://doi.org/10.1038/s41574-023-00886-5

Article  PubMed  Google Scholar 

Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S (2025) Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol S221385872500227X. https://doi.org/10.1016/S2213-8587(25)00227-X

Article  Google Scholar 

Glezer A, Santana MR, Bronstein MD, Donato J, Jallad RS (2023) The interplay between prolactin and cardiovascular disease. Front Endocrinol. https://doi.org/10.3389/fendo.2022.1018090

Article  Google Scholar 

Jiang X-B, Li C-L, He D-S, Mao Z-G, Liu D-H, Fan X, Hu B, Zhu Y-H, Wang H-J (2014) Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 17(3):232–239. https://doi.org/10.1007/s11102-013-0495-z

Article  CAS  PubMed  Google Scholar 

Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S (2003) Endothelial Function, insulin sensitivity and inflammatory markers in hyperprolactinemic Pre-Menopausal women. Eur J Endocrinol 187–193. https://doi.org/10.1530/eje.0.1490187

Arslan MS, Topaloglu O, Sahin M, Tutal E, Gungunes A, Cakir E, Ozturk IU, Karbek B, Ucan B, Ginis Z, Cakal E, Ozbek M, Delibasi T (2014) Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract 20(5):447–451. https://doi.org/10.4158/EP13173.OR

Article  PubMed  Google Scholar 

Arcopinto M, D’Assante R, Auriemma RS, Pirchio R, Pivonello R, Bossone E, Colao A, Cittadini A (2023) Early left ventricular diastolic dysfunction in females with chronic hyperprolactinemia: a doppler echocardiographic study. JCM 12(4):1658. https://doi.org/10.3390/jcm12041658

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X-B, Zhang J, Li C, Mao Z-G, Hu B, Zhu Z, Zhu Y-H, Wang H-J (2017) Subclinical impairment of left ventricular longitudinal function in patients with prolactinomas. Endocr Pract 23(12):1379–1386. https://doi.org/10.4158/EP171985.OR

Article  PubMed  Google Scholar 

Ozdemir ED, Caglar GS, Akgul E, Cengiz SD, Tombak G (2014) The association between prolactin, high-sensitivity c-reactive protein and Framingham risk score in menopause. Gynecol Obstet Invest 78(2):119–123. https://doi.org/10.1159/000362550

Article  CAS  PubMed  Google Scholar 

Samperi I, Lithgow K, Karavitaki N (2019) Hyperprolactinaemia. JCM 8(12):2203. https://doi.org/10.3390/jcm8122203

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papazoglou AS, Leite AR, Moysidis DV, Anastasiou V, Daios S, Borges-Canha M, Giannopoulos G, Neves JS, Ziakas A, Giannakoulas G (2024) Serum prolactin levels and mortality in adults without prolactinoma: a meta-analysis. J Clin Endocrinol Metab 109(8):e1652–e1664. https://doi.org/10.1210/clinem/dgae087

Article  CAS  PubMed  Google Scholar 

Krogh J, Selmer C, Torp-Pedersen C, Gislason G, Kistorp C (2017) Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm Metab Res 49(06):411–417. https://doi.org/10.1055/s-0043-107243

Article  CAS  PubMed  Google Scholar 

Shen Y, Yang Q, Hu T, Wang Y, Chen L, Gao F, Zhu W, Hu G, Zhou J, Wang C, Bao Y (2023) Association of prolactin with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study. Eur J Prev Cardiol 30(14):1439–1447. https://doi.org/10.1093/eurjpc/zwad112

Article  PubMed  Google Scholar 

Soto-Pedre E, Newey PJ, Bevan JS, Leese GP (2017) Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr Connect 6(8):580–588. https://doi.org/10.1530/ec-17-0171

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692

Article  CAS  PubMed  Google Scholar 

Akirov A, Rudman Y, Sharon Y, Shimon I, Kushnir S, Diker-Cohen T (2025) Ischemic stroke risk in patients with dopamine agonist‐treated hyperprolactinemia. J Neuroendocrinol 37(4):e13494. https://doi.org/10.1111/jne.13494

Article  CAS  PubMed  Google Scholar 

Dery L, Shimon I, Rudman Y, Iraqi HM, Kushnir S, Shochat T, Cooper O, Akirov A (2024) Breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia. J Endocrinol Invest 48(3):691–699. https://doi.org/10.1007/s40618-024-02492-2

Article  CAS  PubMed  Google Scholar 

Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, Ramírez-Hernandez G, de la Martínez G, Clapp C (2022) The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne) 13:1001703. https://doi.org/10.3389/fendo.2022.1001703

Article  PubMed  Google Scholar 

Han TS, Hannemann A, Arffman R, Friedrich N, Ittermann T, Wilkening R, Piltonen T, Fry CH, Crujeiras AB, Casanueva FF (2025) The relationship between hypoprolactinemia and cardiometabolic health in women. Eur J Endocrinol 192(5):662–670. https://doi.org/10.1093/ejendo/lvaf101

Article  CAS  PubMed  Google Scholar 

Krysiak R, Kowalcze K, Szkróbka W, Okopień B (2024) Increased cardiometabolic risk in men with hypoprolactinemia: a pilot study. Biomolecules 14(10):1335. https://doi.org/10.3390/biom14101335

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattiuzzi C, Lippi G (2024) Leading causes of US deaths in the 2022. JCM 13(23):7088. https://doi.org/10.3390/jcm13237088

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang V, Chao T-H, Hsieh C-C, Lin C-C, Kao C-H (2015) Cancer risks among the users of ergot-derived dopamine agonists for Parkinson’s disease, a nationwide population-based survey. Parkinsonism Relat Disord 21(1):18–22. https://doi.org/10.1016/j.parkreldis.2014.10.015

Article  PubMed  Google Scholar 

Toulis KA, Robbins T, Reddy N, Balachandran K, Gokhale K, Wijesinghe H, Cheng KK, Karavitaki N, Wass J, Nirantharakumar K (2018) Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf) 88(1):71–76. https://doi.org/10.1111/cen.13498

Article  CAS  PubMed  Google Scholar 

Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr 7(1):99. https://doi.org/10.1186/s13098-015-0094-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krysiak R, Kowalcze K, Okopień B (2022) Cardiometabolic profile of young women with hypoprolactinemia. Endocrine 78(1):135–141. https://doi.org/10.1007/s12020-022-03145-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard V, Young J, Binart N (2019) Prolactin — a pleiotropic factor in health and disease. Nat Rev Endocrinol 15(6):356–365. https://doi.org/10.1038/s41574-019-0194-6

Article  CAS  PubMed  Google Scholar 

Ghoreshi ZA-S, Akbari H, Sharif-zak M, Arefinia N, Abbasi-Jorjandi M, Asadikaram G (2022) Recent findings on hyperprolactinemia and its pathological implications: A literature review. J Investig Med 70(7):1443–1451. https://doi.org/10.1136/jim-2022-002351

Article  PubMed